Form 4: TransMedics CFO Sells Shares, Exercises Options

TransMedics Group, Inc. CFO Gerardo Hernandez reported exercising stock options and selling common stock, including a 'sell to cover' transaction for tax obligations.

Summary

• Gerardo Hernandez, Chief Financial Officer of TransMedics Group, Inc., reported multiple transactions involving the company's common stock and derivative securities.
• On March 2, 2026, Hernandez sold 375 shares of common stock at a price of $139.12 per share. This sale was specifically to cover tax withholding obligations related to the vesting of restricted stock units, executed as a 'sell to cover' transaction.
• On March 4, 2026, Hernandez exercised stock options to acquire 1,324 shares of common stock at an exercise price of $77.12 per share. Concurrently, these 1,324 shares were sold at a weighted average price of $147.21 per share (ranging from $147.14 to $147.47).
• Also on March 4, 2026, Hernandez exercised additional stock options to acquire 5,912 shares of common stock at an exercise price of $69.84 per share. These 5,912 shares were also simultaneously sold at a weighted average price of $147.21 per share (ranging from $147.14 to $147.47).
• Following these reported transactions, Gerardo Hernandez directly beneficially owns 14,689 shares of TransMedics Group, Inc. common stock.
• Remaining derivative holdings include 3,975 stock options with an exercise price of $77.12 (vesting monthly until February 24, 2029, expiring February 24, 2035) and 13,010 stock options with an exercise price of $69.84 (25% vested on December 2, 2025, with remaining vesting monthly over three years, expiring December 9, 2034).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The transactions are routine for executive compensation and include option exercises at a significant profit, which can be seen as a positive for the executive, but the net effect is a reduction in direct share ownership from the exercised options.

Positives

• The transactions, including the sales, were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled and not based on new, non-public information, which can mitigate concerns about opportunistic insider trading.
• The exercise of stock options at significantly lower prices ($77.12 and $69.84) compared to the sale prices ($147.21) demonstrates a substantial realized gain for the Chief Financial Officer, reflecting value creation from the company's stock performance.

Negatives

• The net effect of the option exercises and subsequent sales on March 4, 2026, was a reduction in the CFO's direct share ownership from those specific option grants.
• The 'sell to cover' transaction, while a common practice for tax obligations, also resulted in a reduction of the CFO's direct equity stake in the company.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under Rule 10b5-1 plans, are common occurrences in publicly traded companies. While these transactions provide transparency into executive compensation and equity management, they typically do not offer direct insights into broader industry trends or competitive dynamics.

Related Party Transactions

• Gerardo Hernandez, CFO, engaged in transactions involving the company's common stock and derivative securities, which are considered related-party dealings.

Stakeholder Impact

• Shareholders may view the sales as routine executive compensation management, especially given the Rule 10b5-1 plan and 'sell to cover' nature of some transactions. The exercise of options at a profit demonstrates value realization for the executive.

Key Dates

Recommendation

The filing details routine insider transactions by the CFO, including exercising stock options and selling shares, some for tax purposes, under a pre-arranged 10b5-1 plan. These actions are typical for executive compensation and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. The transactions reflect personal financial planning rather than a strong bullish or bearish signal.

Keywords

TransMedics Group, TMDX, Gerardo Hernandez, CFO, Insider Transaction, Form 4, Stock Options, Share Sale, Restricted Stock Units, Equity Compensation, Rule 10b5-1